35 results on '"Dalm, V"'
Search Results
2. Association between serum IgG levels and time to first antibiotic prescription in COPD patients
- Author
-
Vanoverschelde, A, primary, Khan, S R, additional, Dalm, V A, additional, Chaker, L, additional, Brusselle, G, additional, Stricker, B H, additional, and Lahousse, L, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Detection of azole-susceptible and azole-resistant Aspergillus coinfection by cyp51A PCR amplicon melting curve analysis
- Author
-
Schauwvlieghe, A. F. A. D, Vonk, A. G, Buddingh, E. P, Hoek, R. A. S, Dalm, V. A, Klaassen, C. H. W, and Rijnders, B. J. A
- Published
- 2017
- Full Text
- View/download PDF
4. Atopic manifestations are underestimated clinical features in various primary immunodeficiency disease phenotypes
- Author
-
de Wit, J, primary, Dalm, V, additional, Totté, JEE, additional, Kamphuis, LSJ, additional, Vermont, CL, additional, van Osnabrugge, FY, additional, van Hagen, PM, additional, and Pasmans, SGMA, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Analyse intermédiaire de la tolérance et des paramètres hématologiques de patients atteints du syndrome APDS traités par lénionisib, inhibiteur de PI3Kδ, dans une étude d’extension ouverte à long terme
- Author
-
Rao, V.K., Rodina, J., Webster, S., Sediva, A., Plebani, A., Shutz, C., Dalm, V., Shcherbina, A., Trizzino, A., Kulm, E., Körholz, J., Lougaris, V., Vandier, D., Amores, X., and Uzel, G.
- Published
- 2023
- Full Text
- View/download PDF
6. Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study
- Author
-
Xue, Laixi, primary, van Bilsen, K., additional, Schreurs, M. W. J., additional, van Velthoven, M. E. J., additional, Missotten, T. O., additional, Thiadens, A. A. H. J., additional, Kuijpers, R. W. A. M., additional, van Biezen, P., additional, Dalm, V. A. S. H., additional, van Laar, J. A. M., additional, Hermans, M. A. W., additional, Dik, W. A., additional, van Daele, P. L. A., additional, and van Hagen, P. M., additional
- Published
- 2020
- Full Text
- View/download PDF
7. Somatostatin Control of Immune Functions
- Author
-
Ferone, D, primary, Lamberts, S, additional, Van Hagen, P, additional, Hofland, L, additional, and Dalm, V, additional
- Published
- 2004
- Full Text
- View/download PDF
8. AB0038 Tbk1: a key regulator and potential treatment target for interferon positive systemic lupus erythematosus and systemic sclerosis
- Author
-
Huijser, E., primary, Bodewes, I., additional, van Helden-Meeuwsen, C., additional, Tas, L., additional, Huizinga, R., additional, Dalm, V., additional, van Hagen, M., additional, Groot, N., additional, Kamphuis, S., additional, van Daele, P., additional, and Versnel, M., additional
- Published
- 2018
- Full Text
- View/download PDF
9. FRI0307 Tbk1 inhibition downregulates expression of interferon type i and the upregulated expression of rig-like receptors and dna-sensing receptors in interferon positive primary sjÖgren’s syndrome patients
- Author
-
Bodewes, I., primary, Huijser, E., additional, van Helden-Meeuwsen, C., additional, Tas, L., additional, Huizinga, R., additional, Dalm, V., additional, van Hagen, M., additional, Groot, N., additional, Kamphuis, S., additional, van Daele, P., additional, and Versnel, M., additional
- Published
- 2018
- Full Text
- View/download PDF
10. A new STAT3 mutation in a family with a primary antibody deficiency
- Author
-
Suratannon, N., Swagemakers, S., Dik, W., Vosse, E. van de, Burg, M. van der, Dalm, V., Spek, P. van der, Driessen, G., and Hagen, P.M. van
- Published
- 2015
11. The effects of hydroxychloroquine on bone turnover
- Author
-
Both, T, primary, van, der Eerden B C J, additional, Koedam, M, additional, Zillikens, M C, additional, van, Laar J A M, additional, Dalm, V A S H, additional, van, Leeuwen H P T M, additional, van, Hagen P M, additional, and van, Daele P L A, additional
- Published
- 2016
- Full Text
- View/download PDF
12. Common variable immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the same disease spectrum
- Author
-
Driessen, G. J., primary, Dalm, V. A. S. H., additional, van Hagen, P. M., additional, Grashoff, H. A., additional, Hartwig, N. G., additional, van Rossum, A. M. C., additional, Warris, A., additional, de Vries, E., additional, Barendregt, B. H., additional, Pico, I., additional, Posthumus, S., additional, van Zelm, M. C., additional, van Dongen, J. J. M., additional, and van der Burg, M., additional
- Published
- 2013
- Full Text
- View/download PDF
13. The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system
- Author
-
Dalm, V. A., Hofland, L. J., Diego Ferone, Croxen, R., Lamberts, S. W., and Hagen, P. M.
14. Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
- Author
-
Dalm, V. A. S. H., Leo Hofland, Cm, Mooy, Marlijn Waaijers, Koetsveld, P., Langerak, Anton W., Frank Staal, Aj, Lely, Lamberts, S. W. J., Hagen, P. M., Internal Medicine, Ophthalmology, and Immunology
15. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study
- Author
-
Liliana Bezrodnik, Vijay G. Sankaran, Silvia Sánchez-Ramón, Peter Mustillo, Michael A. Keller, Isabelle Meyts, Giorgia Bucciol, Yesim Yilmaz Demirdag, Luis Ignacio Gonzalez-Granado, Andrew R. Gennery, Alexandra F. Freeman, Raffaele Badolato, Alain Fischer, Safa Baris, Federica Barzaghi, Sudhir Gupta, Carlo Agostini, Gulbu Uzel, Kissy Guevara-Hoyer, Isabella Quinti, M. Cecilia Poli, Charlotte Cunningham-Rundles, Stephen Jolles, Elif Karakoc-Aydiner, Alessandro Aiuti, Cinzia Milito, Fabian Hauck, Angel Robles-Marhuenda, Stuart G. Tangye, Marco Yamazaki-Nakashimada, Elena Seoane, Sara Elva Espinosa-Padilla, Pierre Yves Jeandel, Kathleen E. Sullivan, Klaus Warnatz, Claire Fieschi, Cedric Bosteels, Alessandro Plebani, Leonardo Oliveira Mendonça, Carla Gianelli, François Vermeulen, Bart N. Lambrecht, Annarosa Soresina, Virgil A. S. H. Dalm, Selma Scheffler-Mendoza, Catherine Paillard, Eduardo López-Granados, Vassilios Lougaris, Ahmet Ozen, Grant Hayman, Nizar Mahlaoui, Yazmin Espinosa, Bénédicte Neven, Giuseppe Spadaro, Roshini S. Abraham, Meyts, Isabelle, Bucciol, Giorgia, Quinti, Isabella, Neven, Bénédicte, Fischer, Alain, Seoane, Elena, Lopez-Granados, Eduardo, Gianelli, Carla, Robles-Marhuenda, Angel, Jeandel, Pierre-Yve, Paillard, Catherine, Sankaran, Vijay G, Demirdag, Yesim Yilmaz, Lougaris, Vassilio, Aiuti, Alessandro, Plebani, Alessandro, Milito, Cinzia, Dalm, Virgil Ash, Guevara-Hoyer, Kissy, Sánchez-Ramón, Silvia, Bezrodnik, Liliana, Barzaghi, Federica, Gonzalez-Granado, Luis Ignacio, Hayman, Grant R, Uzel, Gulbu, Mendonça, Leonardo Oliveira, Agostini, Carlo, Spadaro, Giuseppe, Badolato, Raffaele, Soresina, Annarosa, Vermeulen, Françoi, Bosteels, Cedric, Lambrecht, Bart N, Keller, Michael, Mustillo, Peter J, Abraham, Roshini S, Gupta, Sudhir, Ozen, Ahmet, Karakoc-Aydiner, Elif, Baris, Safa, Freeman, Alexandra F, Yamazaki-Nakashimada, Marco, Scheffler-Mendoza, Selma, Espinosa-Padilla, Sara, Gennery, Andrew R, Jolles, Stephen, Espinosa, Yazmin, Poli, M Cecilia, Fieschi, Claire, Hauck, Fabian, Cunningham-Rundles, Charlotte, Mahlaoui, Nizar, Warnatz, Klau, Sullivan, Kathleen E, Tangye, Stuart G, Meyts, I., Bucciol, G., Quinti, I., Neven, B., Fischer, A., Seoane, E., Lopez-Granados, E., Gianelli, C., Robles-Marhuenda, A., Jeandel, P. -Y., Paillard, C., Sankaran, V. G., Demirdag, Y. Y., Lougaris, V., Aiuti, A., Plebani, A., Milito, C., Dalm, V. A., Guevara-Hoyer, K., Sanchez-Ramon, S., Bezrodnik, L., Barzaghi, F., Gonzalez-Granado, L. I., Hayman, G. R., Uzel, G., Mendonca, L. O., Agostini, C., Spadaro, G., Badolato, R., Soresina, A., Vermeulen, F., Bosteels, C., Lambrecht, B. N., Keller, M., Mustillo, P. J., Abraham, R. S., Gupta, S., Ozen, A., Karakoc-Aydiner, E., Baris, S., Freeman, A. F., Yamazaki-Nakashimada, M., Scheffler-Mendoza, S., Espinosa-Padilla, S., Gennery, A. R., Jolles, S., Espinosa, Y., Poli, M. C., Fieschi, C., Hauck, F., Cunningham-Rundles, C., Mahlaoui, N., Warnatz, K., Sullivan, K. E., Tangye, S. G., Internal Medicine, Neven, Benedicte, Lopez-Grandos, Eduardo, Jeandel, Pierre-Yves, Sankaran, Vijay G., Lougaris, Vassilios, Dalm, Virgil A. S. H., Sanchez-Ramon, Silvia, Ignacio Gonzalez-Granado, Luis, Hayman, Grant R., Mendonca, Leonardo Oliveira, Vermeulen, Francois, Lambrecht, Bart N., Mustillo, Peter J., Abraham, Roshini S., Freeman, Alexandra F., Gennery, Andrew R., Poli, M. Cecilia, Warnatz, Klaus, Sullivan, Kathleen E., and Tangye, Stuart G.
- Subjects
0301 basic medicine ,Male ,inborn errors of immunity ,X-CGD, X-linked chronic granulomatous disease ,CGD, Chronic granulomatous disease ,X-SCID, X-linked severe combined immunodeficiency ,medicine.disease_cause ,Severity of Illness Index ,law.invention ,HSCT, Hematopoietic stem cell transplantation ,0302 clinical medicine ,law ,Risk Factors ,PID, Primary immunodeficiency ,AIHA, Autoimmune hemolytic anemia ,Medicine and Health Sciences ,Immunology and Allergy ,Child ,Immunodeficiency ,education.field_of_study ,COVID-19, Coronavirus disease 2019 ,Middle Aged ,Intensive care unit ,ICU, Intensive care unit ,Child, Preschool ,ALPS, Autoimmune lymphoproliferative syndrome ,Female ,CVID, Common variable immune deficiency ,primary immunodeficiencies ,Adult ,medicine.medical_specialty ,IEI, Inborn errors of immunity ,Adolescent ,hypogammaglobulinemia ,Population ,Immunology ,P, Patient ,03 medical and health sciences ,Young Adult ,immune dysregulation ,Internal medicine ,Intensive care ,Severity of illness ,medicine ,Humans ,education ,Aged ,Retrospective Studies ,AR, Autosomal-recessive ,SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 ,business.industry ,SARS-CoV-2 ,AGS, Aicardi-Goutieres syndrome ,Genetic Diseases, Inborn ,Immunologic Deficiency Syndromes ,Infant, Newborn ,Infant ,COVID-19 ,Retrospective cohort study ,Immune dysregulation ,medicine.disease ,HLH, Hemophagocytic lymphohistiocytosis ,030104 developmental biology ,Primary immunodeficiency ,CID, Combined immunodeficiency ,business ,030215 immunology - Abstract
BACKGROUND: There is uncertainty about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with rare inborn errors of immunity (IEI), a population at risk of developing severe coronavirus disease 2019. This is relevant not only for these patients but also for the general population, because studies of IEIs can unveil key requirements for host defense. OBJECTIVE: We sought to describe the presentation, manifestations, and outcome of SARS-CoV-2 infection in IEI to inform physicians and enhance understanding of host defense against SARS-CoV-2. METHODS: An invitation to participate in a retrospective study was distributed globally to scientific, medical, and patient societies involved in the care and advocacy for patients with IEI. RESULTS: We gathered information on 94 patients with IEI with SARS-CoV-2 infection. Their median age was 25 to 34 years. Fifty-three patients (56%) suffered from primary antibody deficiency, 9 (9.6%) had immune dysregulation syndrome, 6 (6.4%) a phagocyte defect, 7 (7.4%) an autoinflammatory disorder, 14 (15%) a combined immunodeficiency, 3 (3%) an innate immune defect, and 2 (2%) bone marrow failure. Ten were asymptomatic, 25 were treated as outpatients, 28 required admission without intensive care or ventilation, 13 required noninvasive ventilation or oxygen administration, 18 were admitted to intensive care units, 12 required invasive ventilation, and 3 required extracorporeal membrane oxygenation. Nine patients (7 adults and 2 children) died. CONCLUSIONS: This study demonstrates that (1) more than 30% of patients with IEI had mild coronavirus disease 2019 (COVID-19) and (2) risk factors predisposing to severe disease/mortality in the general population also seemed to affect patients with IEI, including more younger patients. Further studies will identify pathways that are associated with increased risk of severe disease and are nonredundant or redundant for protection against SARS-CoV-2. ispartof: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY vol:147 issue:2 pages:520-531 ispartof: location:United States status: published
- Published
- 2021
16. Systemic sclerosis: state of the art on clinical practice guidelines
- Author
-
Jeska K de Vries-Bouwstra, Jacob M van Laar, Ronald F van Vollenhoven, Els Vandecasteele, Alexandre E. Voskuyl, Charissa Frank, Tobias Alexander, Gemma Lepri, Fonseca João Eurico, Eric Hachulla, Angela Tincani, Alexis Mathian, Elisabetta Zanatta, Veronica Codullo, Alberto Sulli, Luc Mouthon, Marco Matucci-Cerinic, Vanessa Smith, Amber Vanhaecke, Gerd R Burmester, Marie Vanthuyne, Frank J. A. van den Hoogen, D. Launay, Matthias Schneider, Maurizio Cutolo, Rosaria Talarico, Yannick Allanore, Ilaria Galetti, Frédéric Houssiau, Virgil A. S. H. Dalm, Alessandra Della Rossa, Cosimo Bruni, Carlo Alberto Scirè, Ulf Mueller-Ladner, Oliver Distler, Stefano Bombardieri, Paolo Airò, Barbara Ruaro, Marta Mosca, Ana Rita Vieira, Immunology, Internal Medicine, Smith, V, Scire, C, Talarico, R, Airo, P, Alexander, T, Allanore, Y, Bruni, C, Codullo, V, Dalm, V, De Vries-Bouwstra, J, Della Rossa, A, Distler, O, Galetti, I, Launay, D, Lepri, G, Mathian, A, Mouthon, L, Ruaro, B, Sulli, A, Tincani, A, Vandecasteele, E, Vanhaecke, A, Vanthuyne, M, Van Den Hoogen, F, Van Vollenhoven, R, Voskuyl, A, Zanatta, E, Bombardieri, S, Burmester, G, Eurico, F, Frank, C, Hachulla, E, Houssiau, F, Mueller-Ladner, U, Schneider, M, Van Laar, J, Vieira, A, Cutolo, M, Mosca, M, Matucci-Cerinic, M, Scirè, Ca, Van den Hoogen, F, Voskuyl, Ae, Eurico, Fj, van Laar, Jm, and Matucci-Cerinic, M.
- Subjects
ERN ReCONNET ,European reference networks ,clinical practice guidelines ,nailfold videocapillaroscopy ,systemic sclerosis ,unmet needs ,European reference network ,Disease ,INTERSTITIAL LUNG-DISEASE ,RECOMMENDATIONS ,DEVELOPING CRITERIA ,PRACTICE PATHWAY ,High morbidity ,0302 clinical medicine ,Fibrosis ,Medicine and Health Sciences ,EXPERT CONSENSUS ,Immunology and Allergy ,030212 general & internal medicine ,skin and connective tissue diseases ,integumentary system ,Interstitial lung disease ,unmet need ,Clinical Practice ,medicine.symptom ,systemic sclerosi ,clinical practice guideline ,medicine.medical_specialty ,Immunology ,Systemic Sclerosis ,NO ,Pharmacological treatment ,Unmet needs ,03 medical and health sciences ,Rheumatology ,medicine ,SIMPLE CAPILLAROSCOPIC DEFINITIONS ,Intensive care medicine ,030203 arthritis & rheumatology ,business.industry ,STEM-CELL TRANSPLANTATION ,medicine.disease ,Sexual dysfunction ,SKIN ULCERS ,FUNCTIONAL DISABILITY ,clinical practice guidelines, ERN ReCONNET, European reference networks, nailfold videocapillaroscopy, systemic sclerosis, unmet needs ,POINTS ,business - Abstract
Systemic sclerosis (SSc) is an orphan disease characterised by autoimmunity, fibrosis of the skin and internal organs, and vasculopathy. SSc may be associated with high morbidity and mortality. In this narrative review we summarise the results of a systematic literature research, which was performed as part of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines or recommendations. Only in the domains ‘Vascular & Ulcers’ (ie, non-pharmacological approach to digital ulcer), ‘PAH’ (ie, screening and treatment), ‘Treatment’ and ‘Juveniles’ (ie, evaluation of juveniles with Raynaud’s phenomenon) evidence-based and consensus-based guidelines could be included. Hence there is a preponderance of unmet needs in SSc referring to the diagnosis and (non-)pharmacological treatment of several SSc-specific complications. Patients with SSc experience significant uncertainty concerning SSc-related taxonomy, management (both pharmacological and non-pharmacological) and education. Day-to-day impact of the disease (loss of self-esteem, fatigue, sexual dysfunction, and occupational, nutritional and relational problems) is underestimated and needs evaluation.
- Published
- 2018
17. Atopic Manifestations Are Underestimated Clinical Features in Various Primary Immunodeficiency Disease Phenotypes.
- Author
-
de Wit J, Dalm VA, Totté JE, Kamphuis LS, Vermont CL, van Osnabrugge FY, van Hagen PM, and Pasmans SG
- Subjects
- Humans, Allergens, Phenotype, Dermatitis, Atopic diagnosis, Dermatitis, Atopic epidemiology, Asthma epidemiology, Food Hypersensitivity, Rhinitis, Allergic, Primary Immunodeficiency Diseases
- Abstract
Background and Objectives: Atopic manifestations are described as a clinical feature of various primary immunodeficiency disease (PID) phenotypes and are frequently reported in combined immunodeficiencies. The prevalence of atopic manifestations in other PIDs remains largely unknown. Objective: To evaluate the prevalence of atopic manifestations in PIDs other than combined immunodeficiencies and to identify in which PIDs atopic manifestations are most common with the aim of improving patient care., Methods: A partner-controlled, questionnaire-based study was performed in pediatric and adult PID patients. Data from diagnostic tests to assess atopic manifestations (ie, diagnostic criteria for atopic dermatitis, spirometry, specific IgE against food and inhalant allergens) were collected from adult patients to confirm patient-reported atopic manifestations., Results: Forty-seven children and 206 adults with PIDs and 56 partner-controls completed the questionnaire. Thirty-five pediatric patients (74.5%) and 164 adult patients (79.6%) reported having experienced 1 or more atopic manifestations compared with 28 partner-controls (50.0%). In the comparison of adult patients with partner-controls, prevalence values were as follows: atopic dermatitis, 49.5% vs 27.3% (P=.003); food allergy, 10.7% vs 1.9% (P=.031); asthma, 55.7% vs 14.8% (P<.001); and allergic rhinitis, 49.8% vs 21.8% (P<.001). The frequency of current atopic manifestations reported by patients was higher than the prevalence based on diagnostic tests (atopic dermatitis, 11.2%; food allergy, 1.9%; asthma 16.4%; and allergic rhinitis, 11.5%)., Conclusion: Atopic manifestations are prevalent clinical features across a broad spectrum of PIDs and, in our cohort, frequently present in patients with combined immunodeficiencies and predominant antibody deficiencies. Atopic manifestations should be evaluated in patients with PIDs.
- Published
- 2023
- Full Text
- View/download PDF
18. Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey.
- Author
-
Israni M, Nicholson B, Mahlaoui N, Obici L, Rossi-Semerano L, Lachmann H, Hayward G, Avramovič MZ, Guffroy A, Dalm V, Rimmer R, Solis L, Villar C, Gennery AR, Skeffington S, Nordin J, Warnatz K, Korganow AS, Antón J, Cattalini M, Amin T, Berg S, Soler-Palacin P, Burns SO, and Campbell M
- Subjects
- Adult, Humans, Child, Adolescent, Young Adult, Europe epidemiology, Prevalence, Immunologic Deficiency Syndromes diagnosis, Immunologic Deficiency Syndromes epidemiology, Immunologic Deficiency Syndromes therapy, Autoimmune Diseases diagnosis, Autoimmune Diseases epidemiology, Autoimmune Diseases therapy, Hereditary Autoinflammatory Diseases
- Abstract
Background: Due to the absence of curative treatments for inborn errors of immunity (IEI), children born with IEI require long-term follow-up for disease manifestations and related complications that occur over the lifespan. Effective transition from pediatric to adult services is known to significantly improve adherence to treatment and long-term outcomes. It is currently not known what transition services are available for young people with IEI in Europe., Objective: To understand the prevalence and practice of transition services in Europe for young people with IEI, encompassing both primary immunodeficiencies (PID) and systemic autoinflammatory disorders (AID)., Methods: A survey was generated by the European Reference Network on immunodeficiency, autoinflammatory, and autoimmune diseases Transition Working Group and electronically circulated, through professional networks, to pediatric centers across Europe looking after children with IEI., Results: Seventy-six responses were received from 52 centers, in 45 cities across 17 different countries. All services transitioned patients to adult services, mainly to specialist PID or AID centers, typically transferring up to ten patients to adult care each year. The transition process started at a median age of 16-18 years with transfer to the adult center occurring at a median age of 18-20 years. 75% of PID and 68% of AID centers held at least one joint appointment with pediatric and adult services prior to the transfer of care. Approximately 75% of PID and AID services reported having a defined transition process, but few centers reported national disease-specific transition guidelines to refer to., Conclusions: Transition services for children with IEI in Europe are available in many countries but lack standardized guidelines to promote best practice., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
19. Did variants in inborn errors of immunity genes contribute to the extinction of Neanderthals?
- Author
-
Zhou Z, M A Swagemakers S, S Lourens M, Suratannon N, J van der Spek P, A S H Dalm V, A Dik W, IJspeert H, and van Hagen PM
- Subjects
- Humans, Animals, Genome, Genome, Human, Membrane Proteins genetics, Neanderthals genetics
- Abstract
Background: Neanderthals were a species of archaic humans that became extinct around 40,000 years ago. Modern humans have inherited 1-6% of Neanderthal DNA as a result of interbreeding. These inherited Neanderthal genes have paradoxical influences, while some can provide protection to viral infections, some others are associated with autoimmune/auto-inflammatory diseases., Objective: We aim to investigate whether genetic variants with strong detrimental effects on the function of the immune system could have potentially contributed to the extinction of the Neanderthal population., Methods: We used the publically available genome information from an Altai Neanderthal and filtered for potentially damaging variants present in genes associated with inborn errors of immunity (IEI) and checked whether these variants were present in the genomes of the Denisovan, Vindija and Chagyrskaya Neanderthals., Results: We identified 24 homozygous variants and 15 heterozygous variants in IEI-related genes in the Altai Neanderthal. Two homozygous variants in the UNC13D gene and one variant in the MOGS gene were present in all archaic genomes. Defects in the UNC13D gene are known to cause a severe and often fatal disease called hemophagocytic lymphohistiocystosis (HLH). One of these variants p.(N943S) has been reported in patients with HLH. Variants in MOGS are associated with glycosylation defects in the immune system affecting the susceptibility for infections., Conclusions: Although the exact functional impact of these three variants needs further elucidation, we speculate that they could have resulted in an increased susceptibility to severe diseases and may have contributed to the extinction of Neanderthals after exposure to specific infections.
- Published
- 2022
- Full Text
- View/download PDF
20. Determinants and Clinical Implications of Thyroid Peroxidase Antibodies in Middle-Aged and Elderly Individuals: The Rotterdam Study.
- Author
-
Khan SR, Peeters RP, van Hagen PM, Dalm V, and Chaker L
- Subjects
- Aged, Alcoholism blood, Alcoholism immunology, Antibodies immunology, Autoantibodies analysis, Autoantibodies blood, Cohort Studies, Female, Humans, Iodide Peroxidase analysis, Logistic Models, Male, Middle Aged, Netherlands, Prospective Studies, Antibodies analysis, Iodide Peroxidase immunology
- Abstract
Background: Thyroid peroxidase antibodies (TPO-Abs) play an important role in autoimmune thyroid disease, but are also prevalent in healthy individuals. However, it is unclear what determinants may influence the occurrence of TPO-Abs in healthy individuals and how TPO-Abs may affect health outcomes in these individuals. We aimed to identify determinants of TPO-Abs in a large, prospective population-based cohort of middle-aged and elderly individuals and to subsequently assess the association between TPO-Abs and risk of overall and cause-specific mortality. Methods: We performed binomial and multinomial logistic regression analyses to obtain odds ratios (ORs) and 95% confidence intervals [95% CIs] for the association of potential determinants based on previous literature with TPO-Ab positivity (>35 kU/L), TPO-Ab detectability (>5 kU/L), and TPO-Ab categories. Cox proportional hazards regression analyses were performed to obtain hazard ratios (HRs) and CIs for the association between TPO-Abs and mortality risk. Results: In 9685 participants (57% women, median baseline age 63.3 years, median follow-up time 10.1 years), we identified female sex (OR = 2.47 [CI 2.13-2.86]) and current smoking (OR = 3.10 [CI 2.66-3.62]) as determinants of TPO-Ab positivity and TPO-Ab detectability, respectively. Higher age (OR = 0.98 [CI 0.97-0.98]) and all categories of alcohol consumption (ORs ranging from 0.71-0.78) were associated with lower odds of TPO-Ab detectability. TPO-Ab detectability was associated with a higher risk of overall (HR = 1.09 [CI 1.01-1.17]), cancer-related (HR = 1.18 [CI 1.01-1.38]), and cardiovascular mortality (HR = 1.21 [CI 1.01-1.45]). Interestingly, this was more prominent in men compared with women (HR for cardiovascular mortality 1.50 vs. 0.99, respectively). Conclusions: In community-dwelling middle-aged and elderly individuals, female sex and current smoking are the most important determinants associated with TPO-Ab levels in the detectable and positive range, whereas alcohol consumption is associated with lower odds of TPO-Abs. The clinical importance of detectable TPO-Ab levels is illustrated by the association with an increased mortality risk, mainly in men. Our results warrant further exploration of the clinical applicability of detectable TPO-Ab levels, potentially as a marker for low-grade inflammation. The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; www.trialregister.nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831.
- Published
- 2022
- Full Text
- View/download PDF
21. A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure.
- Author
-
Detiger SE, Kremer TM, A S H Dalm V, de Keizer ROB, Wubbels RJ, Metselaar JM, van Hagen PM, Peeters RP, and Paridaens D
- Subjects
- Adult, Aged, Female, Follow-Up Studies, Glucocorticoids administration & dosage, Graves Ophthalmopathy diagnosis, Humans, Intravitreal Injections, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Treatment Outcome, Drug Implants, Graves Ophthalmopathy drug therapy, Liposomes administration & dosage, Prednisolone administration & dosage
- Abstract
Purpose: To demonstrate that long-circulating PEGylated liposomal prednisolone is a safe and effective therapy in patients with active moderate-to-severe Graves' orbitopathy., Methods: Open-label, proof-of-concept, multicentre pilot study. Ten patients with moderate-to-severe Graves's orbitopathy, who were euthyroid for at least three months. Long-circulating PEGylated liposomal prednisolone 150 mg was administered intravenously twice, with 2-week interval. Total follow-up was 12 months, with visits at baseline, week 2, 6, 13, 26 and 52. Physical, laboratory and ophthalmological examinations were performed. Response to treatment was defined as a reduction in Clinical Activity Score by ≥2 points; palpebral aperture by ≥3 mm; soft tissue signs by ≥2 grades; exophthalmos by ≥2 mm; and motility by >8 degrees or improvement in diplopia score. A response was sustained when equally observed at weeks 6 and 13., Results: One patient achieved a sustained response according to the predetermined definition. All patients showed a decrease in Clinical Activity Score after one infusion, with a mean decrease of two points. The Clinical Activity Score was ≤1 at week 52 for all patients. Improvement was also observed in the soft tissue signs. Most of the adverse events were mild and of a transient nature. Two patients required further treatment with intravenous methylprednisolone., Conclusion: This pilot study showed a positive effect of long-circulating PEGylated liposomal prednisolone on the Clinical Activity Score in patients with moderate-to-severe Graves's orbitopathy, resulting in fewer hospital visits and possibly less glucocorticoid-related side-effects., (© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
22. MicroRNA-378a-3p is overexpressed in psoriasis and modulates cell cycle arrest in keratinocytes via targeting BMP2 gene.
- Author
-
Soonthornchai W, Tangtanatakul P, Meesilpavikkai K, Dalm V, Kueanjinda P, and Wongpiyabovorn J
- Subjects
- Cell Cycle Checkpoints, Gene Expression Regulation, Humans, Keratinocytes cytology, Keratinocytes metabolism, Psoriasis pathology, Transcriptome, Up-Regulation, Bone Morphogenetic Protein 2 genetics, Keratinocytes pathology, MicroRNAs genetics, Psoriasis genetics
- Abstract
Psoriasis is a chronic autoimmune skin disease driven by dysregulations at the cellular, genomic and genetic levels. MicroRNAs are key mediators of gene expression regulation. However, how microRNAs control the pathogenesis of psoriasis is still unclear. Here, we reported a significant up-regulation of miR-378a-3p (miR-378a) in skin biopsies from active psoriatic lesions while it was down-regulated after treatment with methotrexate or narrow-band ultraviolet B phototherapy. Using the keratinocyte in vitro model, we showed that miR-378a disturbed the cell cycle progression, causing cell cycle arrest at G1 phase. Transcriptomic analysis of keratinocytes with miR-378a overexpression and depletion revealed several important biological mechanisms related to inflammation and tight junction. Target mRNA transcript assessed by luciferase assay identified bone morphogenetic protein 2 as a novel target gene of miR-378a. These findings offer a mechanistic model where miR-378a contributes to the pathogenesis of psoriasis., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
23. Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade ® to Remsima ® ? An Observational Study.
- Author
-
Xue L, van Bilsen K, Schreurs MWJ, van Velthoven MEJ, Missotten TO, Thiadens AAHJ, Kuijpers RWAM, van Biezen P, Dalm VASH, van Laar JAM, Hermans MAW, Dik WA, van Daele PLA, and van Hagen PM
- Abstract
Background: Since the late '90s, infliximab (Remicade
® ) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima® were introduced in clinical practice. Aim: To investigate the interchangeability of Remicade® (originator infliximab) and its biosimilar Remsima® in patients with rare immune-mediated inflammatory diseases (IMIDs). Methods: This two-phased prospective open label observational study was designed to monitor the transition from Remicade® to Remsima® in patients with rare IMIDs. All included patients were followed during the first 2 years. The primary endpoint was the demonstration of non-difference in quality of life and therapeutic efficacy, as measured by parameters including a safety monitoring program, physicians perception of disease activity (PPDA) and patient self-reported outcomes (PSROs). Secondary outcomes included routine blood analysis, pre-infusion serum drug concentration values and anti-drug antibody formation. Results: Forty eight patients treated with Remicade® were switched to Remsima® in June-July 2016 and subsequently monitored during the first 2 years. The group consisted of patients with sarcoidosis ( n = 17), Behçet's disease ( n = 12), non-infectious uveitis ( n = 11), and other diagnoses ( n = 8). There were no significant differences in PPDA, PSROs, clinical and laboratory assessments and pre-infusion serum drug concentrations between the groups. De novo anti-drug antibodies were observed in two patients. Seven patients with sarcoidosis and five with another diagnosis developed a significant disease relapse ( n = 7) or adverse events ( n = 5) within 2 years; 10 of these patients discontinued Remsima® treatment, one withdrew from the study and one received additional corticosteroid therapy. Conclusions: We observed no significant differences in PSROs, PPDA and laboratory parameters after treatment was switched from Remicade® to Remsima® . However, disease relapse or serious events were observed in 12 out of 48 patients when treatment was switched from Remicade® to Remsima® . The choice to switch anti-TNF alpha biologics in patients with rare IMIDs, particularly in sarcoidosis, requires well-considered decision-making and accurate monitoring due to a possibly higher incidence of disease worsening., (Copyright © 2020 Xue, van Bilsen, Schreurs, van Velthoven, Missotten, Thiadens, Kuijpers, van Biezen, Dalm, van Laar, Hermans, Dik, van Daele and van Hagen.)- Published
- 2020
- Full Text
- View/download PDF
24. Systemic sclerosis: state of the art on clinical practice guidelines.
- Author
-
Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, and Matucci-Cerinic M
- Abstract
Systemic sclerosis (SSc) is an orphan disease characterised by autoimmunity, fibrosis of the skin and internal organs, and vasculopathy. SSc may be associated with high morbidity and mortality. In this narrative review we summarise the results of a systematic literature research, which was performed as part of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines or recommendations. Only in the domains 'Vascular & Ulcers' (ie, non-pharmacological approach to digital ulcer), 'PAH' (ie, screening and treatment), 'Treatment' and 'Juveniles' (ie, evaluation of juveniles with Raynaud's phenomenon) evidence-based and consensus-based guidelines could be included. Hence there is a preponderance of unmet needs in SSc referring to the diagnosis and (non-)pharmacological treatment of several SSc-specific complications. Patients with SSc experience significant uncertainty concerning SSc-related taxonomy, management (both pharmacological and non-pharmacological) and education. Day-to-day impact of the disease (loss of self-esteem, fatigue, sexual dysfunction, and occupational, nutritional and relational problems) is underestimated and needs evaluation., Competing Interests: Conflicts of interest: VS, None to declare. CAS, None to declare. RT, None to declare. PA, None to declare. TA, None to declare. YA, consulted for Actelion, Bayer, Roche/Genentech, Inventiva, Medac, Pfizer, Sanofi, Servier, and UCB; and has received research grants from Bristol-Myers Squibb, Roche/Genentech, Inventiva, Pfizer, Sanofi. CB, None to declare. VC, None to declare. VD, None to declare. JVB, None to declare. ADS, None to declare. OD, had consultancy relationship and/or has received research funding from Actelion, AnaMar, Bayer, Boehringer Ingelheim, Catenion, CSL Behring, ChemomAb, Roche, GSK, Inventiva, Italfarmaco, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Sanofi, and UCB in the area of potential treatments ofscleroderma and its complications. In addition, Prof. Distler has a patent mir-29 for the treatment of systemic sclerosis licensed. The real or perceived potential conflicts listed above are accurately stated. IG, None to declare. DL, None to declare. GL, None to declare. AM, None to declare. LM, None to declare. BR, None to declare. AS, None to declare. AT, None to declare. EV, None to declare. AV, None to declare. MV, None to declare. FVH, None to declare. RVV, consulted for AbbVie, AstraZeneca, Biogen, Biotest, BMS, Celgene, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, UCB; and received research support and grants from AbbVie, BMS, GSK, Pfizer, UCB. AV None to declare. EZ, None to declare. SB, None to declare. GB, None to declare. FJE, None to declare. CF, None to declare. EH, None to declare. FH, None to declare. UML, None to declare. MS, None to declare. JML, None to declare. AV, None to declare. MC, None to declare. MM, None to declare. MMC, has consultancy relationship and/or has received research funding for Actelion, BMS, Celgene, Chemomab, CSL Behring, Eli Lilly and Pfizer; and is a member of the college of emeritus presidents of the Italian Society of Rheumatology (SIR).
- Published
- 2018
- Full Text
- View/download PDF
25. Chemotherapy-induced exacerbations of thyroid orbitopathy in a patient with B-cell lymphoma.
- Author
-
Liu C, Dalm VASH, van Hagen PM, Croon-de Boer F, and Paridaens D
- Subjects
- Administration, Oral, Antibodies, Monoclonal, Murine-Derived adverse effects, Cyclophosphamide adverse effects, Doxorubicin adverse effects, Female, Glucocorticoids therapeutic use, Graves Ophthalmopathy diagnostic imaging, Graves Ophthalmopathy drug therapy, Humans, Magnetic Resonance Imaging, Middle Aged, Orbital Diseases diagnostic imaging, Orbital Diseases drug therapy, Prednisolone therapeutic use, Prednisone adverse effects, Rituximab, Vincristine adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Graves Ophthalmopathy chemically induced, Lymphoma, B-Cell drug therapy, Orbital Diseases chemically induced
- Abstract
A 55-year-old woman with concurrent active thyroid orbitopathy and B-cell lymphoma developed acute exacerbation of thyroid orbitopathy after receiving Rituximab, cyclophosphamide, hydroxydaunorubicin, Prednisone (R-CHOP) chemotherapy, presenting with subtotal loss of vision and severe eyelid edema. Intravenous methylprednisolone was fully effective within several hours. Further exacerbations of her orbitopathy were seen following every subsequent chemotherapeutic treatment, but responded well to oral prednisone. This case shows that thyroid orbitopathy may severely and acutely progress after chemotherapy for concurrent B-cell lymphoma. Clinical awareness of this potential complication may prevent blindness in this rare subset of patients.
- Published
- 2018
- Full Text
- View/download PDF
26. MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination.
- Author
-
Eindhoven S, Levels J, Huisman M, de Winter KR, Dalm V, and Alwani R
- Abstract
Background: Although influenza vaccines are generally safe and effective, a variety of autoimmune phenomena have been reported after vaccination over the past years, such as Guillain-Barre syndrome, rheumatoid arthritis, pemphigus vulgaris, psoriasis, giant cell arteritis and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV)., Case Report: We describe the case of a 67-year old man who presented with a myeloperoxidase-ANCA associated vasculitis with renal involvement and mononeuritis multiplex after seasonal influenza vaccination. He was initially treated with intravenous cyclophosphamide and high-dose prednisolone followed by maintenance treatment consisting of azathioprine and prednisolone., Conclusion: We hypothesize that seasonal influenza vaccination triggered a systemic immune response in a susceptible patient to develop AAV with renal involvement and vasculitic neuropathy. In general, seasonal influenza vaccinations are considered to be safe, however, clinicians should be aware of this rare phenomenon.
- Published
- 2017
- Full Text
- View/download PDF
27. Expanding the mutation spectrum in ICF syndrome: Evidence for a gender bias in ICF2.
- Author
-
van den Boogaard ML, Thijssen PE, Aytekin C, Licciardi F, Kıykım AA, Spossito L, Dalm VASH, Driessen GJ, Kersseboom R, de Vries F, van Ostaijen-Ten Dam MM, Ikinciogullari A, Dogu F, Oleastro M, Bailardo E, Daxinger L, Nain E, Baris S, van Tol MJD, Weemaes C, and van der Maarel SM
- Subjects
- Adolescent, Adult, Animals, Centromere pathology, Child, Child, Preschool, DNA Helicases genetics, DNA Methylation genetics, Face abnormalities, Face physiopathology, Female, Genetic Predisposition to Disease, Humans, Immunologic Deficiency Syndromes physiopathology, Male, Mice, Mutation, Missense, Nuclear Proteins genetics, Sexism, Young Adult, DNA Methyltransferase 3B, Centromere genetics, DNA (Cytosine-5-)-Methyltransferases genetics, Immunologic Deficiency Syndromes genetics, Repressor Proteins genetics
- Abstract
Background: Immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome is a rare, genetically heterogeneous, autosomal recessive disorder. Patients suffer from recurrent infections caused by reduced levels or absence of serum immunoglobulins. Genetically, 4 subtypes of ICF syndrome have been identified to date: ICF1 (DNMT3B mutations), ICF2 (ZBTB24 mutations), ICF3 (CDCA7 mutations), and ICF4 (HELLS mutations)., Aim: To study the mutation spectrum in ICF syndrome., Materials and Methods: Genetic studies were performed in peripheral blood lymphocyte DNA from suspected ICF patients and family members., Results: We describe 7 ICF1 patients and 6 novel missense mutations in DNMT3B, affecting highly conserved residues in the catalytic domain. We also describe 5 new ICF2 patients, one of them carrying a homozygous deletion of the complete ZBTB24 locus. In a meta-analysis of all published ICF cases, we observed a gender bias in ICF2 with 79% male patients., Discussion: The biallelic deletion of ZBTB24 provides strong support for the hypothesis that most ICF2 patients suffer from a ZBTB24 loss of function mechanism and confirms that complete absence of ZBTB24 is compatible with human life. This is in contrast to the observed early embryonic lethality in mice lacking functional Zbtb24. The observed gender bias seems to be restricted to ICF2 as it is not observed in the ICF1 cohort., Conclusion: Our study expands the mutation spectrum in ICF syndrome and supports that DNMT3B and ZBTB24 are the most common disease genes., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
28. Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.
- Author
-
Wentink M, Dalm V, Lankester AC, van Schouwenburg PA, Schölvinck L, Kalina T, Zachova R, Sediva A, Lambeck A, Pico-Knijnenburg I, van Dongen JJ, Pac M, Bernatowska E, van Hagen M, Driessen G, and van der Burg M
- Subjects
- Adolescent, Adult, Cell Differentiation immunology, Child, Child, Preschool, Class Ia Phosphatidylinositol 3-Kinase, Female, Humans, Immunoglobulin Class Switching genetics, Immunoglobulin Class Switching immunology, Infections genetics, Lymphocyte Activation genetics, Lymphocyte Activation immunology, Male, Mutation genetics, Mutation immunology, Phosphorylation genetics, Plasma Cells immunology, Precursor Cells, B-Lymphoid immunology, Proto-Oncogene Proteins c-akt genetics, Recurrence, Signal Transduction genetics, Somatic Hypermutation, Immunoglobulin genetics, Somatic Hypermutation, Immunoglobulin immunology, Young Adult, Agammaglobulinemia genetics, Agammaglobulinemia immunology, B-Lymphocytes immunology, Cell Differentiation genetics, Class I Phosphatidylinositol 3-Kinases genetics, Phosphatidylinositol 3-Kinases genetics
- Abstract
Background: Mutations in PIK3CD and PIK3R1 cause activated PI3K-δ syndrome (APDS) by dysregulation of the PI3K-AKT pathway., Methods: We studied precursor and peripheral B-cell differentiation and apoptosis via flowcytometry. Furthermore, we performed AKT-phosphorylation assays and somatic hypermutations (SHM) and class switch recombination (CSR) analysis., Results: We identified 13 patients of whom 3 had new mutations in PIK3CD or PIK3R1. Patients had low total B-cell numbers with increased frequencies of transitional B cells and plasmablasts, while the precursor B-cell compartment in bone marrow was relatively normal. Basal AKT phosphorylation was increased in lymphocytes from APDS patients and natural effector B cells where most affected. PI3K mutations resulted in altered SHM and CSR and increased apoptosis., Conclusions: The B-cell compartment in APDS patients is affected by the mutations in PI3K. There is reduced differentiation beyond the transitional stage, increased AKT phosphorylation and increased apoptosis. This B-cell phenotype contributes to the clinical phenotype., (Copyright © 2017. Published by Elsevier Inc.)
- Published
- 2017
- Full Text
- View/download PDF
29. Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy.
- Author
-
Jonkman-Berk BM, van den Berg JM, Ten Berge IJ, Bredius RG, Driessen GJ, Dalm VA, van Dissel JT, van Deuren M, Ellerbroek PM, van der Flier M, van Hagen PM, van Montfrans JM, Rutgers A, Schölvinck EH, de Vries E, van Beem RT, and Kuijpers TW
- Subjects
- Age Distribution, Europe epidemiology, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Netherlands epidemiology, Prevalence, Registries statistics & numerical data, Risk, Sex Distribution, Immunologic Deficiency Syndromes epidemiology, Neoplasms epidemiology
- Abstract
Purpose: To analyze the data of the national registry of all Dutch primary immune deficiency (PID) patients, according to the European Society for Immunodeficiencies (ESID) definitions., Results: In the Netherlands, 745 patients had been registered between 2009 and 2012. An overall prevalence of 4.0 per 100,000 inhabitants was calculated. The most prevalent PID was 'predominantly antibody disorder (PAD)' (60.4%). In total, 118 transplantations were reported, mostly hematopoietic stem cell transplantations (HSCT). Almost 10% of the PID patients suffered from a malignancy, in particular 'lymphoma' and 'skin cancer'. Compared to the general Dutch population, the relative risk of developing any malignancy was 2.3-fold increased, with a >10-fold increase for some solid tumors (thymus, endocrine organs) and hematological disease (lymphoma, leukemia), varying per disease category., Conclusions: The incidence rate and characteristics of PID in the Netherlands are similar to those in other European countries. Compared to the general population, PID patients carry an increased risk to develop a malignancy., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
30. [Fibrosing disorders: insights into pathogenesis and new treatment options].
- Author
-
Dalm V, Dik WA, Thio HB, van den Blink B, van Hagen PM, and van Daele PL
- Subjects
- Fibroblasts, Fibrosis complications, Fibrosis diagnosis, Humans, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis drug therapy, Interleukin-13 therapeutic use, Scleroderma, Systemic diagnosis, Scleroderma, Systemic drug therapy, Treatment Outcome, Fibrosis drug therapy, Platelet-Derived Growth Factor therapeutic use, Transforming Growth Factor beta therapeutic use
- Abstract
Fibrosis is one of the leading causes of morbidity and mortality in the Western world. This disorder is characterised by an abnormal and increased rate of fibroblast proliferation and by an excessive deposition of connective tissue. The key player in fibrosis is the myofibroblast. Fibrosis leads to loss of organ structure and, eventually, to decrease in organ function. To date, there are hardly any effective therapies for the treatment of patients with fibrosis. Pirfenidone targets the myofibroblast and is effective in the treatment of idiopathic pulmonary fibrosis. Tyrosine kinase inhibitors are effective for the treatment of patients with some forms of systemic sclerosis. Here we describe various novel therapeutic targets, such as transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), interleukin-13 (IL-13), lysyloxidase-2 and macrophage-fibroblast interactions. These new therapies are currently under investigation in pre-clinical and clinical studies.
- Published
- 2015
31. A 56-year-old female with fever and a painful, red, swollen leg.
- Author
-
Dalm VA and Gerth van Wijk R
- Subjects
- Animals, Edema drug therapy, Edema etiology, Female, Fever, Glucocorticoids therapeutic use, Humans, Middle Aged, Prednisone therapeutic use, Skin Diseases drug therapy, Skin Diseases etiology, Syndrome, Culicidae, Edema diagnosis, Insect Bites and Stings complications, Leg pathology, Skin Diseases diagnosis
- Published
- 2010
32. Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field.
- Author
-
Dalm VA, Hofland LJ, and Lamberts SW
- Subjects
- Antineoplastic Agents, Hormonal therapeutic use, Endocrine Gland Neoplasms diagnostic imaging, Endocrine Gland Neoplasms drug therapy, Endocrine Gland Neoplasms metabolism, Endocrine System Diseases drug therapy, Humans, Immune System metabolism, Immune System Diseases diagnostic imaging, Immune System Diseases metabolism, Neoplasms diagnostic imaging, Neoplasms metabolism, Neuropeptides therapeutic use, Radionuclide Imaging, Receptors, Somatostatin agonists, Somatostatin analogs & derivatives, Somatostatin therapeutic use, Endocrine System Diseases metabolism, Neoplasms drug therapy, Neuropeptides metabolism, Neurosecretory Systems metabolism, Receptors, Somatostatin metabolism, Somatostatin metabolism
- Abstract
Somatostatin receptors (sst), somatostatin (SS) and cortistatin (CST) are widely expressed in the various systems in the human and rodent organisms and are "responsible" for maintaining homeostasis, which is essential for survival. Because of their broad expression pattern sst, SS and CST interactions may play regulatory roles in both physiology and pathophysiology in mammalian organisms. SS analogue treatment strategies as well as the use of SS analogues for diagnostic purposes have been established in diseases of different origins. This review focuses on the currently determined role for SS analogues in today's clinical practice and the potential clinical prospects for SS, CST and sst interactions in the future, with a focus on neuroendocrine and non-neuroendocrine tumours and immune-mediated diseases. Moreover, the role of new SS analogues and new insights in sst physiology will be discussed.
- Published
- 2008
- Full Text
- View/download PDF
33. Somatostatin receptor distribution and function in immune system.
- Author
-
Ferone D, van Hagen PM, Semino C, Dalm VA, Barreca A, Colao A, Lamberts SW, Minuto F, and Hofland LJ
- Subjects
- Animals, Autoimmune Diseases immunology, Granulomatous Disease, Chronic immunology, Humans, Immune System cytology, Neoplasms chemistry, Neuropeptides analysis, Rats, Somatostatin analysis, Somatostatin physiology, Tissue Distribution, Immune System immunology, Receptors, Somatostatin analysis
- Abstract
Somatostatin and cortistatin, a recently discovered endogenous neuropeptide relative of somatostatin, have multiple modulatory effects on the immune system. The specific somatostatin receptor distribution might in part explain the heterogeneity of effects of somatostatin or its analogs on immunocytes. In fact, somatostatin receptor subtypes are differentially expressed on specific cell subsets within the organs of the immune system and the expression is dynamically regulated and seems to depend on the traffic of these cells through and within lymphoid structure and homing in tissues. Somatostatin effects on immune cells are mainly based on autocrine and paracrine modes of action. In fact, activated cells producing somatostatin (or cortistatin) may interact with other cells expressing the receptors. Here, we review the postulated modes of action of somatostatin and somatostatin-like peptides, including the currently available synthetic somatostatin analogs, in cells of the immune system. We also discuss the wide distribution of somatostatin and its specific five receptor subtypes in immune cell lines, as well as throughout animal and human lymphoid organs, in both normal and pathological conditions.
- Published
- 2004
- Full Text
- View/download PDF
34. The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis.
- Author
-
Dalm VA, van Hagen PM, and Krenning EP
- Subjects
- Granuloma diagnostic imaging, Granuloma metabolism, Humans, Radiopharmaceuticals pharmacokinetics, Tomography, Emission-Computed methods, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid metabolism, Octreotide analogs & derivatives, Octreotide pharmacokinetics, Receptors, Somatostatin metabolism, Sarcoidosis diagnostic imaging, Sarcoidosis metabolism
- Abstract
Somatostatin receptors are widely expressed on cells and tissues throughout the human body. Apart from their expression in the physiological target organs of the peptide, somatostatin receptors are also expressed in various tumours. The expression of somatostatin receptors on neuroendocrine tumours led to the development of somatostatin receptor scintigraphy using [(111)In-DTPA-D-Phe(1)]-octreotide ((111)In-pentetreotide) in order to visualize somatostatin receptor positive tumours and their metastases in vivo. Previous studies reported the expression of somatostatin receptors in both normal and pathological cells and tissues of the human immune system as well. Somatostatin receptors have been demonstrated in Hodgkin's and non-Hodgkin's lymphomas and sst scintigraphy has shown to be a useful tool in diagnosis and staging of these diseases. Moreover, sst expression has also been detected in granulomateus diseases, like sarcoidosis and auto-immune diseases, like rheumatoid arthritis. In this paper we discuss the (possible) role of somatostatin receptor scintigraphy in diagnosis, staging or follow-up of patients suffering from sarcoidosis and rheumatoid arthritis.
- Published
- 2003
35. The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system.
- Author
-
Dalm VA, Hofland LJ, Ferone D, Croxen R, Lamberts SW, and van Hagen PM
- Subjects
- Animals, Arthritis, Rheumatoid metabolism, Bone Marrow Cells immunology, Bone Marrow Cells metabolism, Granuloma immunology, Granuloma metabolism, Humans, Lymphoma metabolism, Mice, Receptors, Somatostatin classification, Sarcoidosis metabolism, Somatostatin analogs & derivatives, Somatostatin metabolism, Arthritis, Rheumatoid immunology, Leukocytes immunology, Lymphoma immunology, Receptors, Somatostatin immunology, Sarcoidosis immunology, Somatostatin immunology
- Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.